跳至主要内容
临床试验/NCT03012698
NCT03012698已完成不适用

Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye

Epitech Mag Ltd.3 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2017年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
29
试验地点
3
主要终点
Best Corrected Visual Acuity (BCVA)

研究概览

简要总结

The study aims to test the safety of Repetitive Magnetic Stimulation (RMS) treatment for dry eye disease. Patients are asked to undergo a one-time treatment with Epitech Ocular Magnetic Stimulation Device on one eye in the first stage and both eyes sequentially in the second stage of the study. Changes are monitored for over a study period of 3 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females, 18-80 years old
  • Subjects with moderate to severe dry eye syndrome
  • Subjects able to understand the requirements of the protocol and provide informed consent.

排除标准

  • Eyes with other ocular surface pathology which requires more treatment than eye lubricant and conventional eyelid hygiene
  • A concurrent ocular disease including ocular infection or pterygium.
  • Ocular surgery within the previous 6 months and LASIK within the previous 1 year.
  • Any ocular injury or ocular Herpes infection within past 3 months
  • Anticipated necessity to wear contact lens in the duration of the study.
  • Unstable thyroid disorders (Drugs Tx not stable in the last 3 months).
  • Pregnant or nursing women
  • Documented HIV positive
  • Cardiac pacemakers, cardioverter defibrillators, or neurostimulators, cochlear implants, implanted medication pumps or intracardiac lines, implanted brain electrodes (cortical or deep-brain electrodes)
  • Any Conductive, ferromagnetic or other magnetic - sensitive objects such as aneurysm clips or coils, stents, bullet fragments in the head or neck
  • Significant heart disease or cerebrovascular disease
  • History of epilepsy, dementia, head trauma, increased intracranial pressure, or central nervous system (CNS) tumors.
  • Participation in another ophthalmic clinical trial within past 30 day
  • Any other specified reason as determined by the clinical investigator.

结局指标

主要结局

Best Corrected Visual Acuity (BCVA)

时间窗: 3 mounth

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验